NOW APPROVED!
LYTENAVA is the only FDA-approved ophthalmic formulation of bevacizumab indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD).1
IMPORTANT SAFETY INFORMATION
LYTENAVA (bevacizumab-vikg) is a prescription medicine specifically for ophthalmic intravitreal use to treat adults with neovascular (wet) age-related macular degeneration (nAMD).
Contraindications
LYTENAVA is contraindicated in patients with ocular or periocular infections and in patients with a known hypersensitivity to bevacizumab-vikg or any of the excipients in LYTENAVA. Hypersensitivity reactions may manifest as severe intraocular inflammation.
Warnings and Precautions
Intravitreal injections have been associated with endophthalmitis and retinal detachments. Proper aseptic injection techniques should always be used when administering LYTENAVA. In addition, patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay to permit prompt and appropriate management.
Increases in intraocular pressure have been noted post-injection (up to 60 minutes) while being treated with LYTENAVA. Monitor intraocular pressure prior to and following intravitreal injection with LYTENAVA and manage appropriately.
Although there was a low rate of ATEs observed in the LYTENAVA clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).
Adverse Reactions
The most common adverse reaction (≥5%) reported in patients receiving LYTENAVA was conjunctival hemorrhage (5%). These are not all the possible side effects of LYTENAVA.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Outlook Therapeutics at 1-844-444-6855.
Please see the full Prescribing Information for LYTENAVA.